论文部分内容阅读
本文对３６例慢性肝炎（ＣＨ）、２８例肝炎性肝硬化及２９例原发性肝癌患者血清中ＩＬ６、ＩＬ８及ＴＮＦα活性进行了测定。结果表明，慢性肝炎患者ＩＬ６、ＩＬ８及ＴＮＦα活性分别为：１８０．５４±９．６８，１６０．８８±６．１６和２３０．７４±８９．０４ｐｇ／ｍｌ，明显高于对照组（Ｐ＜０．０１）；肝炎性肝硬化患者ＩＬ６、ＩＬ８及ＴＮＦα活性分别为２４６．６７±９．０６，２０３．０４±８．０２和２６７．８５±１０６．８８ｐｇ／ｍｌ，明显高于对照组（Ｐ＜０．００１）；原发性肝病患者ＩＬ６和ＩＬ８活性分别为１０１．１１±８．６４和１０７．４６±４．５８ｐｇ／ｍｌ，与对照组比较，活性明显升高（Ｐ＜０．０５），ＴＮＦα活性为３０６．７８±１５８．６６ｐｇ／ｍｌ，明显高于对照组（Ｐ＜０．０１），并对上述三种细胞因子与慢性肝炎、肝硬化及肝癌的发生发展关系进行了探讨。
In this paper, 36 cases of chronic hepatitis (CH), 28 cases of hepatitis cirrhosis and 29 cases of primary liver cancer serum IL6, IL8 and TNFα activity was measured. The results showed that the levels of IL6, IL8 and TNFα in patients with chronic hepatitis were 180.54 ± 9.68, 160.88 ± 6.16 and 230.74 ± 89.04pg / ml, respectively, which were significantly higher than those in the control group (P <0. .01). The activities of IL6, IL8 and TNFα in patients with hepatic cirrhosis were 246.67 ± 9.06, 203.04 ± 8.02 and 267.85 ± 106.88pg / ml, respectively, which were significantly higher than those in the control group (P <0.001). The activities of IL6 and IL8 in patients with primary liver disease were 101.11 ± 8.64 and 107.46 ± 4.58pg / ml, respectively, which were significantly higher than those in control group (P <0.05 ), The activity of TNFα was 306.78 ± 158.66pg / ml, which was significantly higher than that of the control group (P <0.01), and the relationship between the three cytokines and the occurrence and development of chronic hepatitis, cirrhosis and hepatocellular carcinoma was discussed .